Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 76
Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report Appendix D Meeting Agenda Meeting of the Committee on the Perspectives on the Role of Intermittent Preventive Treatment of Malaria in Infants January 9, 2008–January 11, 2008 American Public Health Association (APHA) 800 I (Eye) Street, N.W. Washington, DC 20001-3710 Main Floor, Conference Room A Wednesday, January 9, 2008—APHA Conference Room A OPEN SESSION 10:15am–10:45am Welcoming Remarks Patrick Kelley, M.D., Dr.P.H. Director, Board on Global Health, IOM Myron M. Levine, M.D., D.T.P.H. Director, Center for Vaccine Development, University of Maryland School of Medicine, and IOM Committee Chair 10:45am–11:15am Remarks from Sponsor (phone conference) David Brandling-Bennett, M.D., D.T.P.H. Project Officer, Bill & Melinda Gates Foundation 11:15am–11:45am Antimalarial Drugs and Drug Resistance Christopher Plowe, M.D., M.P.H. Professor of Medicine, Epidemiology and Preventive Medicine, and Microbiology and Immunology; Chief, Center for Vaccine Development’s Malaria Section, University of Maryland, and IOM Committee Member 11:45am–12:15pm Malaria Overview and Burden of Malaria in Infancy Miriam Laufer, M.D., M.P.H. Assistant Professor of Pediatrics, Division of Infectious Diseases and Tropical Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, and IOM Committee Member 12:15pm–12:45pm Childhood Immunizations/EPI in Developing Country Context Neal Halsey, M.D. Professor, Department of International Health, Johns Hopkins Bloomberg School of Public Health, and IOM
OCR for page 77
Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report Committee Member 12:45pm–1:30pm Lunch 1:30pm–1:45pm Overview of the IPTi Consortium Pedro Alonso, M.D., Ph.D. Director, Barcelona Centre for International Health Research at the Hospital Clinic and Professor at the University of Barcelona 1:45pm–2:15pm Pooled Efficacy of Intermittent Preventive Treatment for Malaria in Infants with Sulfadoxine-Pyrimethamine (IPTi-SP) John Aponte, M.D., M.Sc. Research Professor and Head, Statistics Unit of the Barcelona Centre for International Health Research (CRESIB) 2:15pm–2:30pm Break 2:30pm–4:30pm Acceptability, Cost-Effectiveness, Drug Resistance, Applicability of IPTi-SP, Effectiveness Study of IPTi-SP (five presentations) David Schellenberg, M.B.B.S., D.T.M.H., M.R.C.P., Ph.D. Professor, Malaria and International Health, London School of Hygiene and Tropical Medicine 4:30pm–5:10pm United Nations Children’s Fund (UNICEF) Pilot Implementation of IPTi-SP Alexandra de Sousa, M.D., Ph.D. Operational Research Coordinator, Unit of Policy and Evidence, UNICEF 5:10pm–5:30pm IPTi Consortium Policy Process Andrea Egan, Ph.D. Coordinator, IPTi Consortium 5:30pm–5:40pm Concluding Remarks, Questions, Public Announcement of Change to Next Day’s Schedule with WHO Speaker Starting at 8:15am. Myron M. Levine, M.D., D.T.P.H. IOM Committee Chair Thursday, January 10, 2008—APHA Conference Room A OPEN SESSION 8:15am–9:00am World Health Organization’s Global Malaria Program: Considerations of IPTi-SP Within Context of Malaria Control Program Dr. Peter Olumese, M.B., FMCPaed Case Management and Research Team, Global
OCR for page 78
Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report Malaria Programme, World Health Organization 9:00am–10:10am Pooled Safety of IPTi-SP Sir Alasdair Breckenridge, M.D., M.Sc. Chairman, UK Medicines and Healthcare Products Regulatory Agency 10:10am–10:20am Break 10:20am–10:50am Potential Impact of IPT on Spread of Drug-Resistant Malaria: Considerations from Mathematical Modeling Wendy Prudhomme O’Meara, Ph.D. Research Associate NIH/Fogarty Center, Centre for Geographic Medicine Research, KEMRI-Wellcome Trust Research Center, Kenya 10:50am–11:30am Program Implementation Challenges in a Developing Country Context Carol Medlin, Ph.D., M.P.A. Professor, Anthropology and Social Medicine, University of California, San Francisco 11:30am–12:00pm Kisumu—Results from First Trial of IPTi with Alternative Drugs to Sulfadoxine-Pyrimethamine Larry Slutsker, M.D., M.P.H. Chief, Malaria Branch of the U.S. Centers for Disease Control and Prevention 12:15pm–1:15pm Lunch for Speakers and Registered Guests in Conference Room A CLOSED LUNCH SESSION FOR COMMITTEE, Conference Room C 1:15pm–2:15pm Open Question-and-Answer Session 2:15pm–2:55pm Considerations for the Implementation of IPTi (by phone) Brian Greenwood, M.D. Manson Professor of Clinical Tropical Medicine, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine 2:55pm–3:52pm Public Comment and Question Session 3:52pm Concluding Remarks and Adjournment to Closed Sessions Myron M. Levine, M.D., D.T.P.H. IOM Committee Chair Patrick Kelley, M.D., Dr.P.H. Director, IOM Board on Global Health